Pharming Group (NASDAQ:PHAR) Rating Reiterated by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Pharming Group (NASDAQ:PHAR) in a research report released on Thursday morning, Benzinga reports. HC Wainwright currently has a $37.00 price objective on the stock.

Pharming Group Trading Up 5.1 %

Shares of PHAR traded up $0.42 during mid-day trading on Thursday, hitting $8.72. 2,626 shares of the company’s stock traded hands, compared to its average volume of 4,869. The company has a quick ratio of 2.65, a current ratio of 3.39 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $591.48 million, a P/E ratio of -45.89 and a beta of 0.15. The business’s 50-day moving average price is $8.03 and its 200-day moving average price is $8.56. Pharming Group has a 1 year low of $6.65 and a 1 year high of $13.20.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.01) earnings per share (EPS) for the quarter. Pharming Group had a negative net margin of 4.65% and a negative return on equity of 5.69%. The company had revenue of $74.09 million for the quarter, compared to analysts’ expectations of $71.95 million. During the same period in the previous year, the firm posted $0.02 earnings per share. As a group, sell-side analysts forecast that Pharming Group will post -0.15 EPS for the current fiscal year.

Institutional Trading of Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its position in shares of Pharming Group (NASDAQ:PHAR) by 32.3% during the second quarter, according to its most recent filing with the SEC. The firm owned 23,435 shares of the company’s stock after acquiring an additional 5,725 shares during the period. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 at the end of the most recent quarter. Institutional investors and hedge funds own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.